<DOC>
	<DOCNO>NCT00305708</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , busulfan fludarabine , work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . A donor peripheral blood , bone marrow , umbilical cord blood transplant may able replace blood-forming cell destroy chemotherapy . Sometimes transplanted cell donor make immune response body 's normal cell . Giving antithymocyte globulin transplant may stop happen . PURPOSE : This phase I/II trial study side effect busulfan , antithymocyte globulin , fludarabine give together donor stem cell transplant treat young patient blood disorder , bone marrow disorder , chronic myelogenous leukemia first chronic phase , acute myeloid leukemia first remission .</brief_summary>
	<brief_title>Busulfan , Antithymocyte Globulin , Fludarabine Followed By Donor Stem Cell Transplant Treating Young Patients With Blood Disorders , Bone Marrow Disorders , Chronic Myelogenous Leukemia First Chronic Phase , Acute Myeloid Leukemia First Remission</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy , term graft rejection 4 week , condition regimen comprise busulfan , anti-thymocyte globulin , fludarabine follow donor stem cell transplantation ( SCT ) child stem cell defect , marrow failure syndrome , chronic myelogenous leukemia first chronic phase , acute myeloid leukemia first remission . - Determine pharmacokinetics busulfan child undergo donor SCT . Secondary - Determine toxicity regimen patient . - Determine engraftment 3 , 6 , 9 , 12 month mixed chimerism patient treat regimen . - Determine overall disease-free survival patient treat regimen . OUTLINE : Patients receive one follow cytoreductive regimen : - Regimen 1 ( patient HLA genotypic match sibling donor ) : Patients receive busulfan IV 2 hour every 6 hour day -9 -6 , fludarabine IV day -5 -2 , anti-thymocyte globulin ( ATG ) IV 10 hour day -3 -1 . - Regimen 2 ( patient HLA closely match related [ genotypic ] unrelated donor ) : Patients receive busulfan fludarabine regimen 1 , ATG IV 10 hour day -4 -1 . - Regimen 3 ( patient Fanconi 's anemia severe aplastic anemia genotypic match sibling donor ) : Patients receive fludarabine regimen 1 ATG regimen 2 . - Regimen 4 ( patient Fanconi 's anemia closely match related [ genotypic ] unrelated donor ) : Patients undergo thoracoabdominal irradiation day -6 receive fludarabine regimen 1 ATG regimen 2 . All patient undergo allogeneic bone marrow , umbilical cord blood , peripheral blood stem cell transplantation day 0 . After completion study treatment , patient follow periodically 20 year . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Fanconi Anemia</mesh_term>
	<mesh_term>Fanconi Syndrome</mesh_term>
	<mesh_term>Anemia , Diamond-Blackfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis one follow hematopoietic disorder : Severe aplastic anemia marrow aplasia ( i.e. , absolute neutrophil count &lt; 500/mm^3 , platelet and/or red blood cell transfusion dependent ) , meet 1 follow criterion : Closely match relate donor Unresponsive immunosuppressive therapy within 3 month followup AND alternative match unrelated donor available Congenital marrow failure syndrome , include follow : Primary red blood cell aplasia ( DiamondBlackfan syndrome ) Congenital neutropenia ( Kostmann 's syndrome ) Amegakaryocytic thrombocytopenia Hemoglobinopathy include follow : βthalassemia major Sickle cell anemia Severe immunodeficiency disease include follow : ChediakHigashi disease WiskottAldrich syndrome Combined immunodeficiency disease ( Nezelof 's ) Hyperimmunoglobulin M syndrome Bare lymphocyte syndrome Other stem cell defect ( e.g. , osteopetrosis ) Chronic myelogenous leukemia first chronic phase Not eligible ongoing phase II/III study Acute myeloid leukemia first remission Not eligible ongoing phase II/III study Inborn error metabolism No severe combine immunodeficiency disorder Available donor , meet 1 follow criterion : Related donor match high resolution DNA type HLA Drβ1 alleles ≤ 1 mismatch 4 HLAA B allele Unrelated donor , meet one follow criterion : Bone marrow match high resolution DNA type HLA Drβ1 alleles ≤ 1 mismatch high resolution DNA type 4 HLAA B alleles Umbilical cord blood match 4/6 HLAA , B , Drβ1 alleles high resolution type ≥ 1 Drβ1 match ≥ 3 X 10^7 cells/kg body weight recipient PATIENT CHARACTERISTICS : See Disease Characteristics No active bacterial , viral , fungal infection Cardiac shorten fraction ≥ 27 % Creatinine clearance ≥ 60 mL/min DLCO ≥ 60 % predict ( correct anemia/lung volume ) PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>thrombocytopenia</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>Diamond-Blackfan anemia</keyword>
	<keyword>congenital amegakaryocytic thrombocytopenia</keyword>
	<keyword>Fanconi anemia</keyword>
	<keyword>severe congenital neutropenia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
</DOC>